<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954784</url>
  </required_header>
  <id_info>
    <org_study_id>CASE1A13</org_study_id>
    <secondary_id>NCI-2013-01777</secondary_id>
    <secondary_id>CASE1A13</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <nct_id>NCT01954784</nct_id>
  </id_info>
  <brief_title>Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma</brief_title>
  <official_title>A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of lenalidomide after donor stem&#xD;
      cell transplant and bortezomib in treating patients with high-risk multiple myeloma. Giving&#xD;
      low doses of chemotherapy and total-body irradiation before a donor stem cell transplant&#xD;
      helps stop the growth of cancer cells. It may also the patient's immune system from rejecting&#xD;
      the donor's stem cells. The donated stem cells may replace the patient's immune cells and&#xD;
      help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the&#xD;
      transplanted cells from a donor can also make an immune response against the body's normal&#xD;
      cells. Giving a bortezomib at the time of transplant may stop this from happening. Biological&#xD;
      therapies, such as lenalidomide, may stimulate the immune system in different ways and stop&#xD;
      cancer cells from growing. Giving lenalidomide after donor stem cell transplant may be an&#xD;
      effective treatment for multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Identify the maximal tolerated dose (MTD) and safety of lenalidomide up to 10mg following&#xD;
      non-myeloablative allogeneic stem cell transplant for multiple myeloma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess safety and tolerability of weekly bortezomib following non-myeloablative allogeneic&#xD;
      stem cell transplant.&#xD;
&#xD;
      II. Obtain estimates of non-relapse mortality. III. Obtain estimates of acute and chronic&#xD;
      graft-versus-host disease (GVHD). IV. Obtain estimates of 1 year relapse and survival.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of lenalidomide.&#xD;
&#xD;
      PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo&#xD;
      total body irradiation (TBI) on day -1.&#xD;
&#xD;
      TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant (SCT) on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine orally&#xD;
      (PO) twice daily (BID) beginning on day -1 with taper beginning on day 100, mycophenolate&#xD;
      mofetil PO BID on days 1-56, and bortezomib subcutaneously (SC) weekly from day 1 to day 91.&#xD;
&#xD;
      MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days&#xD;
      1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up monthly for 1 year&#xD;
      post-transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding unavailable&#xD;
  </why_stopped>
  <start_date type="Actual">October 7, 2013</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of lenalidomide defined as one dose level below the dose in which 2 or more patients at a specified dose level experience dose limiting toxicity (DLT) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v. 4.0)</measure>
    <time_frame>Day 128 post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by evaluating the incidence of toxicity according to CTCAE v. 4.0</measure>
    <time_frame>Up to day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD according to Center for International Blood and Marrow Transplant Research (CIBMTR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD according to National Institutes of Health (NIH)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deaths without relapse/recurrence</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From study entry to progression as defined by international response criteria or death of any cause, whichever comes first, assessed at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From study entry to death from any cause, assessed at 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.&#xD;
TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.&#xD;
GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.&#xD;
MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo nonmyeloablative allogeneic hematopoietic SCT</description>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>IMiD-1</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nonmyeloablative alloHSCT, lenalidomide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic multiple myeloma by International Myeloma Working Group (IMWG) criteria&#xD;
             according to the most recent updated version (International Myeloma Workshop [IMW]&#xD;
             meeting in Paris 2011)&#xD;
&#xD;
          -  Must have received at least 3 of the following classes of anti-myeloma agents either&#xD;
             alone or in combination: glucocorticoids, immunomodulatory drugs including&#xD;
             thalidomide, proteasome inhibitors, alkylating chemotherapy, or anthracyclines&#xD;
&#xD;
          -  Must meet any of these criteria for high risk disease:&#xD;
&#xD;
               -  Relapse or progressive disease according to uniform response criteria within 2&#xD;
                  years after starting first-line therapy or within 2 years after autologous stem&#xD;
                  cell transplant&#xD;
&#xD;
               -  Failure to achieve partial response (PR) within 6 months of staring first-line&#xD;
                  therapy&#xD;
&#xD;
               -  Presence of high risk cytogenetic features (t(14;16), t(14;20), deletion 17p)&#xD;
&#xD;
               -  Chromosome 14 translocations other than to chromosome 11&#xD;
&#xD;
               -  Chromosome 1p deletion and 1q amplification&#xD;
&#xD;
               -  MyPRS gene expression score equal or higher than 45.2&#xD;
&#xD;
               -  High risk 70 gene expression profile (MyPRS GEP70TM)&#xD;
&#xD;
               -  Any other high risk genetic profile that is determined by future IMWG consensus&#xD;
                  or by internal myeloma panel consensus; for the latter, any additional criteria&#xD;
                  will be submitted as an addendum&#xD;
&#xD;
               -  Diagnosis with multiple myeloma between the ages of 18-50&#xD;
&#xD;
          -  Must have achieved at least a minor response to any previous regimen according to&#xD;
             adapted European Group for Blood and Marrow Transplantation (EBMT) criteria&#xD;
&#xD;
          -  Must have suitable matched sibling or matched unrelated donor for stem cell source&#xD;
&#xD;
          -  Must be transplant-eligible per institution guidelines&#xD;
&#xD;
          -  Must have estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal&#xD;
             Disease (MDRD) formula or Cockroft-Gault formula of 50mL/min or higher&#xD;
&#xD;
          -  All study participants must be registered into the mandatory Revlimid REMS® program,&#xD;
             and be willing and able to comply with the requirements of Revlimid REMS®&#xD;
&#xD;
          -  Females of childbearing potential must have negative serum or urine pregnancy test and&#xD;
             use acceptable birth control methods&#xD;
&#xD;
          -  Able to take aspirin daily as prophylactic anticoagulation (patients intolerant to&#xD;
             acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants must not:&#xD;
&#xD;
          -  Have known hypersensitivity to thalidomide or lenalidomide&#xD;
&#xD;
          -  Have progressive disease at the time of transplant&#xD;
&#xD;
          -  Uncontrolled concurrent significant medical or psychological co-morbidity&#xD;
&#xD;
          -  Grade 3 peripheral neuropathy&#xD;
&#xD;
          -  Known seropositive for or active viral infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are&#xD;
             seropositive because of hepatitis B virus vaccine are eligible&#xD;
&#xD;
          -  Be females who are pregnant&#xD;
&#xD;
          -  Recent (within 3 years) history of other malignancies, excluding basal cell carcinoma&#xD;
             or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Be currently enrolled in another investigational treatment protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hien K Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

